Bovalto Respi vaccines contain a newly developed combination of viral and bacterial antigens. Merial says the recent vaccine isolates effectively target current European-circulating Bovine Respiratory Disease (BRD) strains. Bovalto antigens are also proven by challenge, including at six months post-vaccination to confirm long-lasting protection.
Henry Berger, Global Head of the Ruminant and Equine Business Unit at Merial, said: "Merial is committed to understanding the needs of cattle producers and delivering unique, targeted solutions. Merial is dedicated to expanding its portfolio of parasiticides, vaccines and other disease prevention solutions, with high-value products like Bovalto Respi, to improve productivity, and keep herds healthy."
Merial highlights that BRD is complex to manage and each year affects an estimated 1.9 million animals1, costing the UK cattle industry around £60 million2. In Ireland BRD is responsible for 30% of deaths in stock under one-year old3.
At a Merial symposium at WBC 2016, Prof. Sandro Cavirani, Director of the Department of Animal Health at the University of Parma, Italy highlighted the importance of successful BRD control programmes in calves to optimise herd immunity and productivity, including early, repeated and targeted BRD vaccination.
Bovalto Respi 3 contains strains of Parainfluenza Virus 3, Bovine Respiratory Syncytial Virus, and Mannheimia haemolytica serotype A1. The combination in Bovalto Respi 4 combines the three pathogens in Bovalto Respi 3, with the added strain of Bovine Viral Diarrhoea Virus (BVDV).
References
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.